Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benkang Shi

Showing results (161-170 of 171) with videos related to

Pageof 18
Sort By:
Cancer Biology & Medicine|February 6, 2024
Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancerNanhui Chen, Zengjun Wang, Ming Chen, et al.
BMC Medicine|May 9, 2025
A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancerXiaolin Lu, Tao Dai, Xue Chen, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2022
Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT)Xinan Sheng, Dingwei Ye, Aiping Zhou, et al.
The Lancet. Oncology|September 4, 2025
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trialAiping Zhou, Pengfei Shen, Juan Li, et al.
Asian Journal of Urology|March 8, 2018
Prostate cancer in Asia: A collaborative reportRui Chen, Shancheng Ren, , et al.
Asian Journal of Urology|February 19, 2019
Application of fluorescence <i>in situ</i> hybridization in the detection of bladder transitional-cell carcinoma: A multi-center clinical study based on Chinese populationLiqun Zhou, Kaiwei Yang, Xuesong Li, et al.
Chinese Medical Journal|April 3, 2023
Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trialChengyuan Gu, Zengjun Wang, Tianxin Lin, et al.
Medcomm|July 24, 2023
Development and validation of a prognostic model incorporating tumor thrombus grading for nonmetastatic clear cell renal cell carcinoma with tumor thrombus: A multicohort studyLe Qu, Hui Chen, Qi Chen, et al.
World Journal of Urology|October 30, 2017
Enhanced recovery after surgery for radical cystectomy with ileal urinary diversion: a multi-institutional, randomized, controlled trial from the Chinese bladder cancer consortiumTianxin Lin, Kaiwen Li, Hao Liu, et al.
Asian Journal of Urology|December 22, 2017
Current status of diagnosis and treatment of bladder cancer in China - Analyses of Chinese Bladder Cancer Consortium databaseKaiwen Li, Tianxin Lin, , et al.
Pageof 18

Showing results (161-170 of 171) with videos related to

Sort By:
Pageof 18
Cancer Biology & Medicine|February 6, 2024
Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancerNanhui Chen, Zengjun Wang, Ming Chen, et al.
BMC Medicine|May 9, 2025
A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancerXiaolin Lu, Tao Dai, Xue Chen, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2022
Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT)Xinan Sheng, Dingwei Ye, Aiping Zhou, et al.
The Lancet. Oncology|September 4, 2025
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trialAiping Zhou, Pengfei Shen, Juan Li, et al.
Asian Journal of Urology|March 8, 2018
Prostate cancer in Asia: A collaborative reportRui Chen, Shancheng Ren, , et al.
Asian Journal of Urology|February 19, 2019
Application of fluorescence <i>in situ</i> hybridization in the detection of bladder transitional-cell carcinoma: A multi-center clinical study based on Chinese populationLiqun Zhou, Kaiwei Yang, Xuesong Li, et al.
Chinese Medical Journal|April 3, 2023
Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trialChengyuan Gu, Zengjun Wang, Tianxin Lin, et al.
Medcomm|July 24, 2023
Development and validation of a prognostic model incorporating tumor thrombus grading for nonmetastatic clear cell renal cell carcinoma with tumor thrombus: A multicohort studyLe Qu, Hui Chen, Qi Chen, et al.
World Journal of Urology|October 30, 2017
Enhanced recovery after surgery for radical cystectomy with ileal urinary diversion: a multi-institutional, randomized, controlled trial from the Chinese bladder cancer consortiumTianxin Lin, Kaiwen Li, Hao Liu, et al.
Asian Journal of Urology|December 22, 2017
Current status of diagnosis and treatment of bladder cancer in China - Analyses of Chinese Bladder Cancer Consortium databaseKaiwen Li, Tianxin Lin, , et al.
Pageof 18